On November 4, 2021 Imago BioSciences, Inc. (Imago) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), reported two abstracts have been accepted for oral presentation at the 63rd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, to be held December 11-14, 2021 (Press release, Imago BioSciences, NOV 4, 2021, View Source [SID1234594540]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ASH 2021 Presentation Details:

Oral Presentation Title: "A Phase 2 Study of the LSD1 Inhibitor IMG-7289 (Bomedemstat) for the Treatment of Advanced Myelofibrosis"
Session Name: Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK inhibitor Therapies for Myelofibrosis
Presentation Date/Time: December 11, 2021, at 12:00 PM ET
Location: Georgia World Congress Center, A411-A412

Oral Presentation Title: "A Phase 2 Study of the LSD1 Inhibitor IMG-7289 (Bomedemstat) for the Treatment of Essential Thrombocythemia (ET)"
Session Name: Myeloproliferative Syndromes: Clinical and Epidemiological: Novel Therapies for MPNs and JAK inhibitors for Myelofibrosis
Presentation Date/Time: Sunday, December 12, 2021, at 9:45 AM ET
Location: Georgia World Congress Center, Hall C1

Abstracts are available on the ASH (Free ASH Whitepaper) meeting website at www.hematology.org.